New study checks MS drug levels in breast milk for nursing moms
NCT ID NCT06444113
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study looks at how much of the multiple sclerosis drug ofatumumab passes into breast milk. It involves 24 breastfeeding women with relapsing MS who start or restart the drug 2-24 weeks after giving birth. Researchers will collect milk and blood samples to measure drug levels, helping understand potential risks to nursing infants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Womens Hospital
Brookline, Massachusetts, 02445, United States
-
Northwestern Medicine Northwestern University
Winfield, Illinois, 60190, United States
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Hamburg, 22179, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Foggia, FG, 71122, Italy
-
Novartis Investigative Site
Bialystok, 15 276, Poland
-
Novartis Investigative Site
Kielce, 25 726, Poland
-
Novartis Investigative Site
Cambridge, CB2 0QQ, United Kingdom
-
Novartis Investigative Site
London, NW1 2BU, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 9DU, United Kingdom
-
Novartis Investigative Site
Salford, M6 8HD, United Kingdom
-
UC Health Neuroscience Ctr
Aurora, Colorado, 80045, United States
-
UCSF
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.